ENDO: Testosterone-Replacement Noninferior to Placebo for Cardiovascular Events

THURSDAY, June 22, 2023 -- For men with preexisting cardiovascular disease or a high risk for cardiovascular disease and hypogonadism, testosterone-replacement therapy is noninferior to placebo for the incidence of major adverse cardiac events,...